Eli Lilly (LLY.US) "drops its stance," teams up with former rival Hims (HIMS.US) to grab a share of the self-pay weight-loss drug market.

Zhitong Finance APP has learned that Eli Lilly (LLY.US) is partnering with Hims & Hers Health Inc. (HIMS.US), leveraging the telehealth company's large customer base to extend the reach of its blockbuster weight-loss drugs to a broader population, thereby boosting sales of medications including its new oral weight-loss drug Foundayo.